Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Library

RxE2

RxE2: Pioneering cost-effective, decentralized clinical trials in the pharmacy sector.

Fargo, ND, US🇺🇸

Founded

Loading

RxE2 Website, Blog & Press Pages - aVenture

RxE2 - Library

rxe2.comCrawled Oct 15, 2026

Topics

Publication type

Search the library

Content origin

Row density

Blog

3 pages

Blog/blog
The article examines specific clinical trial activities for modern pharmacists and describes changes in the role of neighborhood pharmacies.
Resources/resources
The page lists articles on pharmacists’ roles in clinical trials and clinical supply forecasting.
The Vital Difference: Independent Community Pharmacies vs. Chain Pharmacies/the-vital-difference-independent-community-pharmacies-vs-chain-pharmacies
The article compares independent community pharmacies and chain pharmacies, including differences in patient care, services, and community involvement.

Press

1 page

News/news
The page lists news and events, including meetings in Boston and San Diego and a virtual discussion about clinical research through community pharmacy.

Careers & Hiring

1 page

Careers/careers
RxE2 puts community pharmacists at the forefront of community-based clinical trials and aims to make clinical trials a healthcare option for everyone, everywhere.

Team

1 page

Team/our-team
The page lists executives and team members with their job titles.

About

1 page

About/about
RxE2 uses technology to provide patient recruitment, dispensing, counseling, and operational services to the pharmaceutical and biotech industries.

Contact

1 page

Contact us/contact-us
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. RxE2 (701) 492-2050 | rxe2@rxe2.com 4302 13th Ave S, Suite 4326, Fargo, ND 58103

Homepage

1 page

Homepage/
Revolutionize community-based clinical trials with RxE2's hub & spoke model: Independent pharmacies as sites, for convenient access. Leverage trusted community pharmacists to boost recruitment, efficiency, and patient reach, solving 80% of trial delays.